JPRN-UMIN000014710已完成2 期
Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI in EGFR-mutant NSCLC - Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional,observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Obvious interstitial pneumonia or pulmonary fibrosis by chest CT 2)History of severe allergic reaction 3)Complications such as severe infection or severe comobidities 4)Uncontrolled pleural or pericardial effusion 5)Clinically significant heart disease 6)Uncontrolled hypertension 7)Uncontrolled diabate 8)Active multiple cancer 9)Squamous histology 10)Aparent invasion of main vessels 11)Clinically significant phycological problem 12)History of significant hemoptysis or respiratory bleeding 13)History of GI perfolation 14)non-curable bone fracture or severe injury 15)Planning surgery 16)Significant lung cavitation 17)Bleeding tendency 18)Uncontrolled thromboembolism 19)Prior therapy of EGFR-TKI+bevacizumab 20)History of Afatinib administration 21)Pregnancy 22)Inadequate patients whom physitians considered
研究者
相似试验
已完成
1 期
Afatinib with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutation:phaseI studyon-small cell lung cancerJPRN-UMIN000015944Okayama Lung Cancer Study Group (OLCSG)24
已完成
2 期
Afatinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring active EGFR mutations : an open-label, randomized, multicenter, phase II studyon-squamous non-small cell lung cancerJPRN-UMIN000027432Okayama University100
招募中
2 期
Afatinib plus Bevacizumab Combination after osimertinib failure for aDvanced EGFR-mutant non-small cell lung cancer: a multicenter prospective single arm phase II study (ABCD-study)on-small cell lung cancerJPRN-UMIN000030545Hanshin Oncology Group26
已完成
1 期
Phase I study of afatinib + bevacizumab for advanced NSCLC with EGFR mutatioon-small cell lung cancerJPRN-UMIN000016029Juntendo University20
已完成
2 期
Afatinib Plus Bevacizumab After Osimertinib Failure(ABCD-study/ HANSHIN Oncology Group 0217 trial))Lung cancerung canerJPRN-jRCTs051180205Hata Akito28